Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu –PSMA PET/CT) in a patient with prostate cancer

Document Type : Case report

Authors

Institute of Nuclear Medicine with PET-Center, Klinik Ottakring, Vienna, Austria

Abstract

Prostate cancer is considered to be the most common solid cancer affecting men worldwide and leading to a significant morbidity and mortality.  Metastases are usually seen in bone or lymph nodes. For recurrent disease, PET imaging with 68Ga-PSMA-11 (also known as HBED-CC, Glu-urea-Lys(Ahx)-HBED-CC, and PSMA-HBED-CC) is widely used. However, preparation of 68Ga-PSMA ligand requires the presence of radiochemistry facilities and can therefore not be utilized in centers lacking such facilities. Recently, copper labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) demonstrated promising results in patients with recurrent disease and in the primary staging of selected patients with progressive local disease. In the present case, a rare manifestation site of a metastatic lesion in a patient with advanced prostate cancer is detected by 64Cu-PSMA PET/CT.

Keywords

References

1. Pianou NK, Stavrou P, Evangelia Vlontzou M, Phivi Rondogianni M, Demetrios N, Exarhos M, et al. More advantages in detecting bone and soft tissue metastases 18 from prostate cancer using F-PSMA PET/CT. Hell J Nucl Med. 2019; 22:6-9.
2. Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. The Quarterly Journal of Nuclear Medicine and
Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of. 2015; 59(4):381-99.
3. Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European journal of nuclear medicine and molecular imaging. 2017; 44(8):1258-68.
4. Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. 64Cu-PSMA-617 PET/CT imaging of prostate adeno-carcinoma: first in-human studies. Cancer Biotherapy and Radiopharmaceuticals. 2016; 31(8): 277-86.
5. Mirzaei S, Mohammed F, Zandieh S. Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals. Current Radio-pharmaceuticals. 2020. (E-pub Ahead of Print)
6. Mirzaei S, Revheim M-E, Raynor W, Zehetner W, Knoll P, Zandieh S, et al. 64 Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors. Oncology and therapy. 2020; 8(1):125-31.
7. Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine. 2019; 60(6):777-85.
8. Mirzaei S, Lipp RW. Peptide and pseudo-peptide (PSMA) Cu-64 radiopharmaceu-ticals. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharma-cology (IAR), [and] Section of the Society of. 2020. 64(4):364-370
9. Ramogida CF, Orvig C. Tumour targeting with radiometals for diagnosis and therapy. Chemical Communications.2013; 49(42): 4720-39.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 9, Issue 2
July 2021
Pages 180-182

Files

Share

How to cite

Statistics